NCT00343863View on ClinicalTrials.gov

Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer

NACompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Male Breast CancerNausea and VomitingStage I Breast CancerStage II Breast CancerStage IIIA Breast Cancer
Interventions
DRUG

palonosetron hydrochloride

Given IV

DRUG

cyclophosphamide

Given orally

DRUG

dexamethasone

Given orally or IV

DRUG

doxorubicin hydrochloride

Given IV

PROCEDURE

quality-of-life assessment

Ancillary studies

PROCEDURE

nausea and vomiting therapy

Given IV

PROCEDURE

management of therapy complications

Given IV

DRUG

ondansetron hydrochloride

Given IV

OTHER

survey administration

Ancillary studies

Trial Locations (1)

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER

NCT00343863 - Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer | Biotech Hunter | Biotech Hunter